Status:
COMPLETED
Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection
Lead Sponsor:
Baqiyatallah Medical Sciences University
Collaborating Sponsors:
Baqiyatallah Research Center for Gastroenterology and Liver Diseases
Tehran Hepatitis Center
Conditions:
Hepatitis C
Hemophilia
Eligibility:
All Genders
12+ years
Phase:
PHASE4
Brief Summary
Hemophilic patients are a known high risk groups for acquiring the hepatitis C. The surveillance data from Ministry Of Health in IR.Iran had shown that 60% of them are infected with HCV infection. We ...
Detailed Description
The investigators enroll 400 patients into the study. The patients receive PEGASYS (Peginterferon alpha-2a(40 KD)) 180 microgram per week plus COPEGUS (Ribavirin) 800 microgram for Genotype 2 and 3 an...
Eligibility Criteria
Inclusion
- HCV RNA positive
- Age older than 12 years
Exclusion
- Ongoing pregnancy or breast feeding
- Hx of HCC
- Hx of alcoholic liver disease
- Hx of bleeding from esophageal varices
- Hx of hemochromatosis
- Hx of autoimmune hepatitis
- Hx of Suicidal attempt
- Hx of cerebrovascular dis
- Hx of severe retinopathy
- Hx of severe psoriasis
- Hx of scleroderma
- Hx of metabolic liver disease
- Hx of SLE
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2009
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00707772
Start Date
March 1 2007
End Date
September 1 2009
Last Update
September 17 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baqiyatallah Research Center for Gastroenterology and Liver Diseases
Tehran, Tehran Province, Iran, 14155-3651